These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 36720180)

  • 1. Serum soluble BCMA can be used to monitor relapse of multiple myeloma patients after chimeric antigen receptor T-cell immunotherapy.
    Shen Y; Liu J; Wang B; Zhang Y; Xu Y; Wang X; Jia Y; Meng X; Wang X; Fan X; He A; Zhao W
    Curr Res Transl Med; 2023; 71(2):103378. PubMed ID: 36720180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical analysis of the correlation between the expression of soluble B cell maturation antigen and the efficacy of chimeric antigen receptor T cell targeting B cell maturation antigen in patients with multiple myeloma].
    Gao SQ; Mu J; Li X; Wang J; Cui R; Li JY; Sui T; Deng Q
    Zhonghua Xue Ye Xue Za Zhi; 2024 Apr; 45(4):378-382. PubMed ID: 38951066
    [No Abstract]   [Full Text] [Related]  

  • 3. Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma.
    Chekol Abebe E; Yibeltal Shiferaw M; Tadele Admasu F; Asmamaw Dejenie T
    Front Immunol; 2022; 13():991092. PubMed ID: 36119032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma.
    Seipel K; Porret N; Wiedemann G; Jeker B; Bacher VU; Pabst T
    Curr Issues Mol Biol; 2022 Mar; 44(4):1463-1471. PubMed ID: 35723356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma.
    Pont MJ; Hill T; Cole GO; Abbott JJ; Kelliher J; Salter AI; Hudecek M; Comstock ML; Rajan A; Patel BKR; Voutsinas JM; Wu Q; Liu L; Cowan AJ; Wood BL; Green DJ; Riddell SR
    Blood; 2019 Nov; 134(19):1585-1597. PubMed ID: 31558469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
    Berdeja JG; Madduri D; Usmani SZ; Jakubowiak A; Agha M; Cohen AD; Stewart AK; Hari P; Htut M; Lesokhin A; Deol A; Munshi NC; O'Donnell E; Avigan D; Singh I; Zudaire E; Yeh TM; Allred AJ; Olyslager Y; Banerjee A; Jackson CC; Goldberg JD; Schecter JM; Deraedt W; Zhuang SH; Infante J; Geng D; Wu X; Carrasco-Alfonso MJ; Akram M; Hossain F; Rizvi S; Fan F; Lin Y; Martin T; Jagannath S
    Lancet; 2021 Jul; 398(10297):314-324. PubMed ID: 34175021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials.
    Que Y; Xu M; Xu Y; Almeida VDF; Zhu L; Wang Z; Wang Y; Liu X; Jiang L; Wang D; Li C; Zhou J
    Front Immunol; 2021; 12():755866. PubMed ID: 34777368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.
    Brudno JN; Maric I; Hartman SD; Rose JJ; Wang M; Lam N; Stetler-Stevenson M; Salem D; Yuan C; Pavletic S; Kanakry JA; Ali SA; Mikkilineni L; Feldman SA; Stroncek DF; Hansen BG; Lawrence J; Patel R; Hakim F; Gress RE; Kochenderfer JN
    J Clin Oncol; 2018 Aug; 36(22):2267-2280. PubMed ID: 29812997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma.
    Yang J; Zhou W; Li D; Niu T; Wang W
    Cancer Lett; 2023 Jan; 553():215949. PubMed ID: 36216149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma.
    Feng D; Sun J
    Scand J Immunol; 2020 Aug; 92(2):e12910. PubMed ID: 32471019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparison of single infusion of anti-BCMA versus combined infusion of anti-CD19 chimeric antigen receptor T cells for immune reconstruction in relapsed/refractory multiple myeloma].
    Ge J; Zhao TT; Wan CY; Xia JY; Guo SY; Yu MX; Chen J; Wang Y; Xu KL; Li ZY
    Zhonghua Xue Ye Xue Za Zhi; 2021 Sep; 42(9):733-738. PubMed ID: 34753227
    [No Abstract]   [Full Text] [Related]  

  • 12. Long event-free survival after anti-BCMA CAR-T cell treatment for relapsed and refractory multiple myeloma patients: Two case reports.
    Xu J; Ming X; Wang C; Xu B; Xiao Y
    Medicine (Baltimore); 2021 May; 100(18):e25784. PubMed ID: 33950974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
    Anderson LD; Dhakal B; Jain T; Oluwole OO; Shah GL; Sidana S; Perales MA; Pasquini MC
    Transplant Cell Ther; 2024 Jan; 30(1):17-37. PubMed ID: 37913909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic potential of third-generation chimeric antigen receptor T cells targeting B cell maturation antigen for treating multiple myeloma.
    Rujirachaivej P; Siriboonpiputtana T; Luangwattananun P; Yuti P; Wutti-In Y; Choomee K; Sujjitjoon J; Chareonsirisuthigul T; Rerkamnuaychoke B; Junking M; Yenchitsomanus PT
    Clin Exp Med; 2024 Apr; 24(1):90. PubMed ID: 38683232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma.
    Jagannath S; Jackson CC; Schecter JM; Lendvai N; Sun H; Akram M; Patel N; Martin TG
    Expert Opin Biol Ther; 2024 May; 24(5):339-350. PubMed ID: 38738379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Chimeric Antigen Receptor T Cell Expansion Is Associated with Prolonged Progression-Free Survival for Patients with Relapsed/Refractory Multiple Myeloma Treated with Ide-Cel: A Retrospective Monocentric Study.
    Caillot L; Sleiman E; Lafon I; Chretien ML; Gueneau P; Payssot A; Pedri R; Lakomy D; Bailly F; Guy J; Quenot JP; Avet-Loiseau H; Caillot D
    Transplant Cell Ther; 2024 Jun; 30(6):630.e1-630.e8. PubMed ID: 38458477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma.
    Martin TG; Madduri D; Pacaud L; Usmani SZ
    Future Oncol; 2023 Nov; 19(34):2297-2311. PubMed ID: 37497629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinician and administrator perspectives on outpatient administration of ciltacabtagene autoleucel in relapsed or refractory multiple myeloma.
    Hansen DK; Dhakal B; Hamadani M; Dingli D; Jain T; Huff CA; Janakiram M; Liu YH; De Braganca KC; Lodowski N; Sander J; Okorozo P; McFarland L; Perciavalle M; Huo S; Qureshi ZP; Patel KK
    Front Immunol; 2024; 15():1405452. PubMed ID: 38915401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ciltacabtagene autoleucel for the treatment of multiple myeloma.
    Holstein SA
    Drugs Today (Barc); 2023 Jan; 59(1):1-16. PubMed ID: 36811414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial.
    Cowan AJ; Pont MJ; Sather BD; Turtle CJ; Till BG; Libby EN; Coffey DG; Tuazon SA; Wood B; Gooley T; Wu VQ; Voutsinas J; Song X; Shadman M; Gauthier J; Chapuis AG; Milano F; Maloney DG; Riddell SR; Green DJ
    Lancet Oncol; 2023 Jul; 24(7):811-822. PubMed ID: 37414012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.